Inhibitors of interleukin-1.beta. converting enzyme
CA 2274249 A1 · Owner: Robidoux, Andrea L. C. · Inventors: Nyce, Philip L.; Mullican, Michael D.; Golec, Julian M. C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme ("ICE"). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be , advantageously used as agents against interleukin-1-("IL-1") apoptosis-, interferon-.gamma. inducing factor-(IGIF) interferon-.gamma.-("IFN-.gamma.") , mediated diseases excess dietary alcohol intake diseases or viral diseases, including inflammatory diseases autoimmune diseases, destructive bone disorders, proliferative …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 5, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 5, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 5, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.